BR112022026720A2 - Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas - Google Patents
Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmasInfo
- Publication number
- BR112022026720A2 BR112022026720A2 BR112022026720A BR112022026720A BR112022026720A2 BR 112022026720 A2 BR112022026720 A2 BR 112022026720A2 BR 112022026720 A BR112022026720 A BR 112022026720A BR 112022026720 A BR112022026720 A BR 112022026720A BR 112022026720 A2 BR112022026720 A2 BR 112022026720A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- methods
- recombinant
- reduced protease
- protease sensitivity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
SIALIDASES RECOMBINANTES COM SENSIBILIDADE À PROTEASE REDUZIDA, PROTEÍNAS DE FUSÃO DE SIALIDASE E MÉTODOS DE USO DAS MESMAS. A presente invenção refere-se, de modo geral, às sialidases recombinantes (por exemplo, sialidases recombinantes que têm sensibilidade à protease reduzida), proteínas de fusão recombinantes e conjugados de anticorpo, e seu uso no tratamento de câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063047989P | 2020-07-03 | 2020-07-03 | |
US202163134411P | 2021-01-06 | 2021-01-06 | |
PCT/US2021/040240 WO2022006492A2 (en) | 2020-07-03 | 2021-07-02 | Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022026720A2 true BR112022026720A2 (pt) | 2023-01-24 |
Family
ID=79317685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022026720A BR112022026720A2 (pt) | 2020-07-03 | 2021-07-02 | Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230265406A1 (pt) |
EP (1) | EP4176056A2 (pt) |
JP (1) | JP2023532021A (pt) |
KR (1) | KR20230034320A (pt) |
CN (1) | CN115803047A (pt) |
AU (1) | AU2021299565A1 (pt) |
BR (1) | BR112022026720A2 (pt) |
CA (1) | CA3173145A1 (pt) |
IL (1) | IL299559A (pt) |
MX (1) | MX2023000243A (pt) |
WO (1) | WO2022006492A2 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3735458A4 (en) | 2018-01-03 | 2022-04-27 | Palleon Pharmaceuticals Inc. | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2014010943A (es) * | 2012-03-16 | 2014-11-26 | Genentech Inc | Proteinas estabilizadas conformacionalmente de ingenieria. |
CN107002110A (zh) * | 2014-10-10 | 2017-08-01 | 恩细贝普有限公司 | 用具有改善的合成水解比的枯草杆菌蛋白酶变体的肽片段缩合和环化 |
EP3463447A4 (en) * | 2016-06-03 | 2020-05-27 | Icahn School of Medicine at Mount Sinai | INFLUENZA VIRUSES |
EP3735458A4 (en) * | 2018-01-03 | 2022-04-27 | Palleon Pharmaceuticals Inc. | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF |
-
2021
- 2021-07-02 CN CN202180047881.0A patent/CN115803047A/zh active Pending
- 2021-07-02 JP JP2022580142A patent/JP2023532021A/ja active Pending
- 2021-07-02 WO PCT/US2021/040240 patent/WO2022006492A2/en active Application Filing
- 2021-07-02 IL IL299559A patent/IL299559A/en unknown
- 2021-07-02 KR KR1020237003002A patent/KR20230034320A/ko unknown
- 2021-07-02 CA CA3173145A patent/CA3173145A1/en active Pending
- 2021-07-02 MX MX2023000243A patent/MX2023000243A/es unknown
- 2021-07-02 BR BR112022026720A patent/BR112022026720A2/pt unknown
- 2021-07-02 US US18/003,234 patent/US20230265406A1/en active Pending
- 2021-07-02 EP EP21833741.8A patent/EP4176056A2/en active Pending
- 2021-07-02 AU AU2021299565A patent/AU2021299565A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230265406A1 (en) | 2023-08-24 |
WO2022006492A3 (en) | 2022-02-17 |
JP2023532021A (ja) | 2023-07-26 |
KR20230034320A (ko) | 2023-03-09 |
MX2023000243A (es) | 2023-03-03 |
CN115803047A (zh) | 2023-03-14 |
AU2021299565A1 (en) | 2023-02-02 |
WO2022006492A2 (en) | 2022-01-06 |
CA3173145A1 (en) | 2022-01-06 |
IL299559A (en) | 2023-02-01 |
EP4176056A2 (en) | 2023-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017930A2 (pt) | Anticorpos anticoronavírus e métodos de uso | |
CO2021006092A2 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas | |
AR115418A1 (es) | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS | |
MX2020007024A (es) | Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas. | |
PE20210313A1 (es) | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso | |
BR112021026789A2 (pt) | Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas | |
BR112022026720A2 (pt) | Sialidases recombinantes com sensibilidade à protease reduzida, proteínas de fusão de sialidase e métodos de uso das mesmas | |
BR112015013319A2 (pt) | lâmina cirúrgica ultrassônica | |
BR112018074759A2 (pt) | artigo absorvente | |
BR112022022937A2 (pt) | Proteínas de fusão estabilizadas de proteína de pico de coronavírus | |
DOP2021000145A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
BR112023020123A2 (pt) | Agentes heterobivalentes e homobivalentes que alvejam proteína alfa de ativação de fibroblasto alfa e/ou antígeno de membrana específico da próstata | |
BR112022004575A2 (pt) | Anticorpos de antígenos de vírus antioncolíticos e métodos de uso dos mesmos | |
BR112022013255A2 (pt) | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo | |
ES2115622T3 (es) | Clones moleculares de hiv-1 y usos de los mismos. | |
BR112022020453A2 (pt) | Anticorpos anti-cd98 e usos dos mesmos | |
CO2023016731A2 (es) | Anticuerpos específicamente unidos a la proteína asm | |
NO20050216L (no) | Steroidkonjugater samt fremstilling og anvendelse derav | |
Cheng et al. | SPARC fusion protein induces cellular adhesive signaling | |
BR112021013096A2 (pt) | Tratamento de doença de sjögren com proteínas de fusão de nuclease | |
BR112020027063A2 (pt) | Tratamento de dor de cabeça com uso de anticorpos anti-cgrp | |
BR112023022079A2 (pt) | Estrutura de carroceria de veículo, e, veículo | |
US10345301B2 (en) | Method for treating infection of group A streptococcus | |
Sefiddashti et al. | A 53 KDa glycan antigen of hydatid cyst wall may involve in evasion from host immune system | |
BR102020007149A8 (pt) | Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca |